Apatinib is a multi-targeted tyrosine kinase inhibitor, which mainly targets vascular endothelial growth factor receptor-2 (VEGFR2) kinase as well as platelet-derived growth factor receptor β (PDGFR-β) and c-kit; it plays the anti-tumor role by inhibiting neovascularization [14–16]. The gene discussed is KDR; the disease is neoplasm.